OligoPhore siRNA targeting NF-\u03baB

OligoPhore siRNA targeting NF-\u03baB is a **preclinical RNA therapeutic** from **Altamira Therapeutics** that uses the company's OligoPhore extrahepatic delivery platform to transport a **small interfering RNA directed against the p65 subunit of NF-\u03baB** into target cells. The construct is described as a **polyplex nanoparticle biologic** built around a proprietary **21-amino acid peptide carrier**, enabling delivery of siRNA payloads to inflamed or tumor tissues while reducing hepatic clearance. By silencing **RELA/p65**, the therapy is intended to suppress NF-\u03baB transcriptional signaling and thereby produce **anti-inflammatory and antitumor effects**. This program appears to represent the platform-level NF-\u03baB-targeting siRNA construct rather than a single branded commercial product, and it has been reported in **preclinical development** with activity in murine models of inflammatory disease, melanoma lung metastasis, and adult T-cell leukemia lymphoma; the rheumatoid arthritis candidate **AM-411** is a more specific downstream drug candidate derived from this platform concept.

Other names

OligoPhore siRNA targeting NF-\u03baBOligoPhore siRNA targeting NF-kBOligoPhore siRNA targeting p65NF-\u03baB p65-targeting OligoPhore siRNA